Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Voyager Therapeutics, Inc. develops genetic medicines and other neurotherapeutics for neurological diseases, with company updates focused on its CNS pipeline and delivery platforms. Recurring news covers the TRACER AAV capsid discovery platform, intravenous gene-therapy research, Voyager NeuroShuttle nonviral delivery work, and programs addressing Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, ALS, frontotemporal dementia and other central nervous system disorders.
Company announcements also cover tau-focused assets such as VY1706 and VY7523, small-molecule discovery collaboration targeting TDP-43 pathology, scientific conference presentations, and periodic financial and operating results. Voyager’s updates frequently connect pipeline spending, collaboration revenue, partner programs and balance-sheet resources with its genetic-medicine development strategy.
Voyager Therapeutics (NASDAQ: VYGR) will release its Q2 2020 financial results and corporate updates on August 10, 2020, before U.S. markets open. The company is focused on gene therapy for severe neurological diseases and will participate in three virtual investor conferences from August 10 to August 12. These events highlight Voyager's commitment to advancing AAV gene therapy and its pipeline targeting therapies for diseases like Parkinson's and Huntington's.
Voyager Therapeutics (NASDAQ: VYGR) announced an employment agreement with a new hire that includes inducement awards of stock options and restricted stock units. The stock option grant of 36,000 shares has an exercise price of $12.82 per share, matching the closing price on the grant date of June 15, 2020. The option vests over four years, while the restricted stock units for 6,000 shares vest annually over three years starting July 1, 2020. These awards were approved by the Compensation Committee in compliance with Nasdaq rules, reflecting the company's commitment to attracting talent.
Voyager Therapeutics reported its Q1 2020 financial results, ending with over $250M in cash, projected to fund operations until mid-2022. The company highlighted 14 presentations at the upcoming ASGCT meeting, addressing several therapies for neurological diseases including Huntington’s and ALS. Voyager established a new Scientific Advisory Board with industry experts to enhance its research efforts. Collaboration revenues increased to $18.1M, up from $5.2M in Q1 2019, while R&D expenses rose to $32.3M due to ongoing clinical trials.
Summary not available.